What is MyBiosource?
MyBioSource operates as a prominent provider of research reagents and life science products. The company boasts a comprehensive catalog that includes ELISA kits, antibodies, recombinant proteins, and peptides. MyBioSource distinguishes itself through its specialization in custom ELISA kit production and offers a broad spectrum of molecular biology reagents designed to cater to the needs of researchers globally. With an extensive inventory of over 2 million life science products, the company aims to be a one-stop shop for cost-effective solutions, particularly supporting COVID-19 research efforts. Its primary clientele consists of researchers and laboratories within the life sciences domain seeking dependable and swift delivery of high-quality reagents.
How much funding has MyBiosource raised?
MyBiosource has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for MyBiosource?
The substantial late-stage funding indicates MyBiosource is poised for significant scaling and strategic growth. This investment will likely fuel advancements in product development, expansion of its research reagent portfolio, and enhancement of its global distribution network. The company's focus on providing cost-effective solutions and supporting critical research areas like COVID-19 suggests a strategy geared towards solidifying its market leadership and exploring new avenues for innovation in the competitive life science industry. Future capital deployment may target acquisitions or partnerships to further broaden its technological capabilities and market reach.
See full MyBiosource company page
